Brokerages Set Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) PT at $11.56

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has been given an average rating of “Buy” by the ten brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $11.50.

A number of brokerages recently commented on CATX. Piper Sandler lowered their price objective on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Wedbush reaffirmed an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a report on Tuesday, May 5th. BTIG Research reiterated a “buy” rating on shares of Perspective Therapeutics in a research report on Friday, July 24th. BMO Capital Markets set a $11.00 price objective on shares of Perspective Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday. Finally, Bank of America cut their price objective on Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Friday, August 14th.

Institutional Trading of Perspective Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its stake in shares of Perspective Therapeutics by 15.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock worth $4,758,000 after purchasing an additional 188,887 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Perspective Therapeutics by 118.4% during the second quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock worth $2,573,000 after buying an additional 405,612 shares in the last quarter. Walleye Capital LLC raised its position in shares of Perspective Therapeutics by 375.8% in the second quarter. Walleye Capital LLC now owns 187,403 shares of the company’s stock valued at $645,000 after buying an additional 148,013 shares during the last quarter. Federated Hermes Inc. lifted its stake in shares of Perspective Therapeutics by 44.4% during the second quarter. Federated Hermes Inc. now owns 195,080 shares of the company’s stock valued at $671,000 after buying an additional 60,019 shares during the period. Finally, Bank of America Corp DE lifted its stake in shares of Perspective Therapeutics by 8.5% during the second quarter. Bank of America Corp DE now owns 327,500 shares of the company’s stock valued at $1,127,000 after buying an additional 25,697 shares during the period. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Stock Performance

CATX opened at $3.21 on Tuesday. Perspective Therapeutics has a 1-year low of $1.96 and a 1-year high of $6.16. The stock’s 50 day simple moving average is $3.11 and its 200 day simple moving average is $3.95.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.03. The firm had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.09 million. Perspective Therapeutics had a negative return on equity of 41.92% and a negative net margin of 28,467.97%. On average, equities analysts expect that Perspective Therapeutics will post -1.03 EPS for the current year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.